Table 1.
Clinical characteristics and volumetric measurements (N = 107).
| All subjects | |
|---|---|
| N = 107 | |
| Donor, N (%) | 49 (45.8) |
| Age, years | 59.1 ± 12.6 |
| Male, N (%) | 50 (46.7) |
| Hypertension, N (%) | 54 (50.5) |
| Duration of hypertension, years | 9 (4–12) |
| Diabetes mellitus, N (%) | 17 (15.9) |
| Duration of diabetes mellitus, years | 3 (2–8) |
| Obesity, N (%) | 37 (34.6) |
| CKD stage G1 and G2, N (%) | 65 (60.7) |
| CKD stage G3, N (%) | 36 (33.6) |
| CKD stage G4 and G5, N (%) | 6 (5.6) |
| Body weight, kg | 61.3 ± 12.1 |
| Body height, cm | 161.7 ± 7.9 |
| Cr, mg/dL | 0.80 (0.68–1.02) |
| eGFR, ml/min/1.73 m2 | 64.4 ± 19.9 |
| Albumin, mg/dL | 3.98 ± 0.58 |
| Serum total cholesterol, mg/dL | 203 ± 39 |
| Hemoglobin A1c, % | 5.6 ± 0.8 |
Abbreviations: CKD, chronic kidney disease; Cr, creatinine; eGFR, estimated glomerular filtration rate.
Values are shown as mean ± standard deviation, median (interquartile range) or number (percentage).
P values refer to comparisons between the derivation group and the validation group.